Antitrust Antitrust

Glenmark, Merck to face Zetia end payors’ pay-for-delay claims after US court certifies class

By Max Fillion
  • 23 Aug 2021 18:34
  • 23 Aug 2021 18:34
Drugmakers Glenmark and Merck will face end payors’ claims they engaged in an illegal pay-for-delay agreement regarding the cholesterol drug Zetia, after the Virginia federal judge overseeing the case certified the class on Friday.

In certifying the class — composed of self-insured health and welfare plans or insurers that indirectly purchased or

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

LEARN MORE LEARN MORE

Latest News